证券日报网讯2月25日，乐心医疗（300562）在互动平台回答投资者提问时表示，截至2026年2月13日， 公司股东总户数为23363户。 ...

联影医疗公告称，2025年度实现营业总收入138.21亿元，同比增长34.18%；归属于母公司所有者的净利 润18.88亿元，同比增长49.60%；扣除非经常性损益的净利润17.88亿元，同比增长77.01%。2025年末， 公司总资产328.00亿元，同比增长17%；归属于母公司的所有者权益215.90亿元，同比增长8.48%。业绩 增长得益于创新产品导入、全球市场布局深化等，未来整体经营规模与运营质效有望进一步提升。数据 为初步核算，未经审计。 ...

联影医疗(688271.SH)公告称，联影医疗发布2025年度业绩快报，营业总收入达到138.2亿元，同比增长 34.18%。归属于母公司所有者的净利润为18.88亿元，同比增长49.60%。主要因素包括创新产品推出、 高端市场认可提升、海外业务增长等。本公告数据为初步核算，具体以年度报告为准。 ...

1，Medtronic糖尿病业务分拆公司MiniMed拟定7.42亿美元IPO条款 从Medtronic糖尿病管理设备和技术业务剥离出来的MiniMed集团周二公布了其首次公开募股（IPO）的 条款。 这家总部位于加州诺斯里奇的公司计划通过发行2800万股股票，以每股25至28美元的价格区间筹集7.42 亿美元。 作为Medtronic剥离出来的公司，MiniMed专注于一体化糖尿病管理，产品包括胰岛素输注装置、持续血 糖监测仪（CGM）、输注管路、储液器、胰岛素笔系统以及相关软件和服务。截至2025年10月，该公 司胰岛素泵用户超过64万人，截至2025年10月24日的六个月内，其CGM的安装率达到65%（上年同期 为58%）。约83%的总收入来自CGM、其他耗材、软件和服务，这体现了其持续性销售模式的稳健性。 MiniMed集团成立于1983年，截至2025年10月31日的12个月内，营收达29亿美元。该公司计划在纳斯达 克上市，股票代码为MMED。高盛、美国银行证券、花旗集团、摩根士丹利、巴克莱银行、德意志银 行、瑞穗证券、富国证券、Evercore ISI和Piper Sandler担任此次交易的联席 ...

华福证券指出，TPD赛道研发火热，蛋白降解技术在自身免疫疾病领域进展迅速，STAT6、IRAK4、 IRF5、VAV1、NLRP3、NEK7等热门小分子靶点备受关注。目前这些靶点在临床或临床前阶段展现出 优异疗效与安全性，为自免疾病治疗开辟新路径。2026年开始，众多自免TPD靶点将迎来数据读出，或 进入到临床关键性阶段。对于医疗器械行业，设备方面关注补库和招投标，如手术机器人和内镜等；耗 材方面关注集采受益的创新耗材，如神经介入、外周介入和电生理等方向。 创业板医药ETF国泰（159377）跟踪的是创医药指数（399275），单日涨跌幅限制达20%，该指数从沪 深市场中选取从事生物制药、化学制药、中药及医疗服务等创新医药健康领域的上市公司证券作为指数 样本，以反映创新生物医药相关上市公司证券的整体表现。指数注重成分企业的研发投入与技术领先 性，聚焦于具有高成长潜力的医药健康板块。 （文章来源：每日经济新闻） 风险提示：提及个股仅用于行业事件分析，不构成任何个股推荐或投资建议。指数等短期涨跌仅供参 考，不代表其未来表现，亦不构成对基金业绩的承诺或保证。观点可能随市场环境变化而调整，不构成 投资建议或承诺。提及 ...

分红方面，春立医疗A股上市后累计派现4.40亿元。近三年，累计派现3.90亿元。 机构持仓方面，截止2025年9月30日，春立医疗十大流通股东中，香港中央结算有限公司位居第四大流 通股东，持股295.85万股，为新进股东。中欧景气精选混合A（020876）位居第五大流通股东，持股 283.26万股，为新进股东。平安低碳经济混合A（009878）位居第八大流通股东，持股210.00万股，相 比上期减少167.00万股。南方医药保健灵活配置混合A（000452）退出十大流通股东之列。 声明：市场有风险，投资需谨慎。本文基于第三方数据库自动发布，不代表新浪财经观点，任何在本文 出现的信息均只作为参考，不构成个人投资建议。如有出入请以实际公告为准。如有疑问，请联系 biz@staff.sina.com.cn。 融券方面，春立医疗2月24日融券偿还200.00股，融券卖出0.00股，按当日收盘价计算，卖出金额0.00 元；融券余量200.00股，融券余额4480.00元，超过近一年70%分位水平，处于较高位。 资料显示，北京市春立正达医疗器械股份有限公司位于北京市通州区通州经济开发区南区鑫觅西二路10 号，成立日期19 ...

Group 1 - The A-share pharmaceutical sector rebounded, with medical device stocks and AI healthcare concepts leading the gains, including Meinian Health and Lepu Medical rising over 3% [1] - The largest medical ETF in the market (512170) saw a near 1% increase, with a net subscription of 77.77 million yuan on the previous day [1][5] - A new policy from the Beijing-Tianjin-Hebei region aims to enhance clinical trial efficiency and reduce compliance costs for CXO and medical device companies, set to take effect on March 1, 2026 [3] Group 2 - The pharmaceutical sector stabilized, with innovative drug concepts showing mixed results; Sanofi's stock rose over 3%, while Dizhe Pharmaceutical fell over 4% [3] - The only ETF tracking the pharmaceutical index (562050) turned positive during trading [3] - The FDA's recent announcement to establish a single pivotal clinical trial as the default standard for new drug approvals is expected to shorten development cycles and lower capital costs, benefiting innovative drug companies [4]

城市建设启新程，地区发展谱新篇。近日，《北京昌平老城和南邵生态组团CP00—0801等街区控制性 详细规划（街区层面）（2021年—2035年）》正式获批，明确了该片区城市功能核心承载区的定位，提 出围绕"魅力永安、花园新城"的目标，推动片区文化、生态与生活空间深度融合。作为该片区的重要组 成部分，位于昌平区南邵镇的昌平新城东区眼下塔吊林立、建设正酣，住宅品质提升、商业层级升级、 公共服务体系完善等各项工作正有条不紊地推进，为片区的发展注入源源不断的活力。 早在2021年，昌平新城东区的发展概念便已正式提出。作为昌平区落实北京市2035年总体规划的关键抓 手，新城东区是昌平新城"一主三副、一带一廊"空间布局的核心组成部分，明确定位为京北体验消费示 范区、山水宜居典范城区、高水平综合服务承载区和智慧产研创新园区，肩负着激活城市发展动能、提 升区域核心竞争力的重要使命。 昌平新城东区拥有得天独厚的发展优势，区位、生态、配套、产业等多重红利叠加。这里北倚燕山山 脉，有东沙河、孟祖河、京密引水渠三水环绕，毗邻白浮泉公园与沙河湿地公园，规划生态空间达202 公顷，人均绿地面积达16.4平方米，生态资源丰富、宜居禀赋突出 ...

Group 1 - The A-share pharmaceutical sector has rebounded, with medical device stocks and AI healthcare concepts leading the gains, including significant increases in companies like Meinian Health and Lepu Medical [1][8] - The largest medical ETF in the market (512170) saw a nearly 1% increase, with a net subscription of 77.77 million yuan the previous day [1][8] - A new policy from the Beijing-Tianjin-Hebei region is expected to benefit CXO and medical device companies by improving clinical trial efficiency and reducing compliance costs [2][5][10] Group 2 - The FDA has announced a new default standard for drug approvals, allowing for a single key clinical trial plus confirmatory evidence, which is projected to shorten development cycles and reduce capital costs significantly [4][12] - The cost of a single key trial is estimated to range from 30 million to 150 million USD, which will enhance the research efficiency of innovative drug companies [4][12] - The medical ETF (512170) has over 50% weight in medical devices and more than 25% in CXO, covering 12 AI medical and brain-computer interface concept stocks [4][12] Group 3 - The pharmaceutical sector is stabilizing, with mixed performance among innovative drug concepts; companies like Sanofi and Dizhiyuan have shown notable fluctuations [2][10] - Traditional Chinese medicine stocks have generally risen, with companies like Darentang and Jilin Aodong seeing increases of over 2% [2][10] - The only ETF tracking the pharmaceutical index (562050) turned positive during trading, indicating a recovery in the sector [2][10]

Core Viewpoint - The medical device sector is experiencing a rebound, driven by policy support, technological advancements, and a shift towards domestic innovation and global competition [1][4]. Group 1: Medical Device Sector Performance - On February 25, the medical device sector saw a rebound with the medical device index ETF (159898) rising by 0.90%, following a net subscription of 1.67 million yuan the previous trading day [1]. - Key stocks such as Aidi Te, Zhend Medical, and Lepu Medical saw significant gains, with Aidi Te rising over 5% and others like Hualan Biological and Yuyue Medical also showing strong performance [1]. Group 2: Brain-Computer Interface Developments - The brain-computer interface (BCI) sector is accelerating, with significant policy backing and capital investment. A semi-invasive BCI company, Borui Kang, is preparing for a listing on the Sci-Tech Innovation Board [4]. - The global BCI market is projected to grow from approximately $2.62 billion in 2024 to $12.4 billion by 2034, with a compound annual growth rate (CAGR) of 17.35% [4]. - In China, the BCI market is expected to reach 3.2 billion yuan in 2024 and grow to 6.14 billion yuan by 2028 [4]. Group 3: Export Resilience and Growth - China's medical device exports demonstrated strong resilience, with a total export value of $45.542 billion in the first 11 months of 2025, marking a year-on-year increase of 3.82% [5]. - The export structure is evolving, with significant growth in high-end products such as hospital diagnostic and treatment equipment, which increased by 8.36% [5]. Group 4: Domestic Market and Innovation - The implementation of the fifth batch of national high-value medical consumables procurement has significantly reduced prices, such as the cost of cochlear implants dropping from over 200,000 yuan to around 50,000 yuan [7]. - The domestic medical device market is projected to reach 1,017.4 billion yuan by 2026, with a CAGR of approximately 5.9% to 6.6% from 2020 to 2035, driven by aging population, equipment upgrades, and technological innovation [7]. - In 2025, a total of 3,402 medical device products were approved, including 76 innovative devices, maintaining a high approval rate for three consecutive years [7]. Group 5: ETF Performance - The medical device index ETF (159898) tracks the CSI All Medical Device Index, focusing on the medical equipment, consumables, and in vitro diagnostics sectors, with a notable exposure to the BCI concept at 23.79% [9]. - Since its inception, the ETF has achieved a total return of 1,015.07%, with an annualized return of 12.52% and a one-year annualized return of 20.86% [9]. - The revenue and net profit of the ETF's constituent stocks have shown a year-on-year recovery, indicating a gradual improvement in the industry's fundamentals [9].